A phase 1, single-center, randomized, double-blind, placebo-controlled, dose-increasing study to evaluate the effects of single dose, multiple dose and food on pharmacokinetics of QY201 tablet tablets in healthy subjects
Latest Information Update: 30 Oct 2023
At a glance
- Drugs QY 201 (Primary)
- Indications Atopic dermatitis
- Focus Adverse reactions; Pharmacokinetics
- Sponsors E-nitiate Biopharmaceuticals
Most Recent Events
- 12 Sep 2023 Results (n=94) assessing developing a population pharmacokinetics and pharmacodynamics model using Phase 1 study data to characterize the PK and PD of QY201 inhealthy Chinese adults presented at the 2023 American College of Clinical Pharmacology Annual Meeting
- 29 Jun 2022 New trial record